Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
about
Dovitinib enhances temozolomide efficacy in glioblastoma cells.Metastatic breast cancer: Endocrine therapy landscape reshaped.Emerging data on improving response to hormone therapy: the role of novel targeted agents.Association of fibroblast growth factor receptor 1 gene amplification with poor survival in patients with esophageal squamous cell carcinoma.ERα Binding by Transcription Factors NFIB and YBX1 Enables FGFR2 Signaling to Modulate Estrogen Responsiveness in Breast Cancer.Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidenceThe efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials
P2860
Q40214485-65B9B078-E0E6-40A4-9FFD-B0EA4C16473FQ45072397-EB4FAF0D-E5F9-478D-95DF-DB0E828E5BEFQ46537162-B293CDCE-E96E-4310-B5E7-6FD86D830A12Q47131297-9403FE12-4E75-4ADF-A103-EE4B4C2332CCQ49587575-8088C3F5-1641-4F83-86E1-AA98C015D5EDQ50048638-F9AE3569-BDDE-4225-A9A7-F92D7076A5A3Q57107345-50414911-4D4F-4867-BF90-007CCFFC9816Q58710786-637E3BE3-4647-474C-A7E1-4B35C6D16362
P2860
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 February 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@en
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@nl
type
label
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@en
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@nl
prefLabel
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@en
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@nl
P2093
P2860
P50
P1476
Phase II, randomized, placebo- ...... after prior endocrine therapy.
@en
P2093
Carlos H Barrios
Hatem Soliman
Hervé Bonnefoi
Kimberly Blackwell
Mario Campone
Matthew Squires
Michael M Shi
Neelima Denduluri
Patrick Neven
Stephanie Deudon
P2860
P2888
P356
10.1186/S13058-017-0807-8
P577
2017-02-10T00:00:00Z
P6179
1083737892